Johnson & Johnson (JNJ)$234.34
Research Snapshot
Static fundamentals, valuation context, and investor signals for Johnson & Johnson (JNJ).
Valuation
20.0x
EV/FCF, 5.0% FCF yield
Quality
21.8%
ROIC, 20.9% FCF margin
Growth
2.7%
5Y sales (revenue) CAGR
Balance sheet
0.5x
Debt/equity, 1.0x current ratio
Superinvestors
14
Top: Tweedy Browne Co. (4.3%)
Strengths to research
- Return on equity is strong at 32.9%.
- Free cash flow margin is healthy at 20.9%.
- Debt/equity looks manageable at 0.5x.
- 14 tracked superinvestors report a position.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Quality Scorecard
Build-time composite score for JNJ.
Peer Comparison
Target stock against 8 market-cap comparable peers.
| JNJ Target | Johnson & Johnson | $372.9B | 21.2x | 20.0x | 21.8% | 2.7% | 20.9% | 67.9% | N/A | N/A |
| ABBV | AbbVie Inc. | $346.8B | 91.4x | 22.8x | 6.9% | 6.0% | 29.1% | N/A | 3.7x | N/A |
| NVO | Novo Nordisk A S | $305.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHBY | Roche Holding AG ADR | $265.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHVF | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| LLY | Eli Lilly & Co. | $737.7B | 46.4x | 43.4x | 77.8% | 21.6% | 25.8% | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
Financial Charts
No financial data available for JNJ (annual).
14 superinvestors own JNJ
Current quarter ownership and quarter-over-quarter share changes.
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Yacktman Asset Management Yacktman Asset Management | 1,249,409 | $305M | 4.07% | 0.0% |
| Thomas Gayner Markel Group | 610,800 | $149M | 1.25% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 577,590 | $141M | 1.44% | 0.0% |
| Tweedy Browne Co. Tweedy Browne Value Fund | 219,490 | $54M | 4.26% | 0.0% |
| Richard Pzena Hancock Classic Value | 203,965 | $50M | 0.16% | 0.0% |
| Prem Watsa Fairfax Financial Holdings | 73,400 | $18M | 0.92% | 0.0% |
| John Rogers Ariel Appreciation Fund | 40,553 | $10M | 0.11% | 0.0% |
| Robert Olstein Olstein Capital Management | 24,500 | $6M | 1.31% | 0.0% |
| Dodge & Cox Dodge & Cox | 20,947 | $5M | 0.00% | 0.0% |
| Jensen Investment Management Jensen Investment Management | 9,767 | $2M | 0.05% | 0.0% |
| Charles Bobrinskoy Ariel Focus Fund | 14,285 | $2M | 3.14% | ▼ -27.4% |
| Torray Funds Torray Funds | 4,141 | $1M | 0.16% | 0.0% |
| David Katz Matrix Asset Advisors | 1,622 | $396,000 | 0.04% | 0.0% |
| Thomas Russo Gardner Russo & Quinn | 1,304 | $319,000 | 0.00% | 0.0% |